Fundraising FoxRA Capital — 2022 Investments
13 investments dated 2022 · listed companies and verified rows first · show all
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.
BiotechHealthtechRadnor, US
Eric Warren(Chief Commercial Officer)inAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)
BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in
Board seatDerek DiRocco· per SEC Form D
Co-investorsAndera PartnersHBM Healthcare InvestmentsHBM PartnersSamsara BioCapitalSR One Capital ManagementYsios Capital+3 more
Capacity Bio is a biotechnology company developing mitophagy modulators — small molecules, peptides, and nanoparticles that target mitochondrial biology to identify and clear dysfunctional mitochondria.
BiotechDeep TechLongevityPalo Alto, US
Amy Wang(PhD)inKenneth Horne(Executive Officer, Director)inDylan Morris(Director)inCristina Ghenoiu(Director)in
BoardTaro Inaba(Director)in
Co-investorsRemiges Ventures, Inc.Insight PartnersAN Venture PartnersRDiscovery
Empatica offers an FDA-cleared health monitoring platform combining medical wearables and digital biomarkers to collect continuous, clinical-quality health data from daily life.
AI & Machine LearningDigital HealthHealthtechMedical DevicesCambridge, US
Rosalind Picard(Founder)inMatteo Lai(Executive Officer, Director)inSimone Tognetti(Director)inLen Picard(Executive Officer, Director)inMario Scuderi(Director)
Co-investorsBlack Opal VenturesCDP Venture CapitalSanofi VenturesInnogest Capital
Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.
AI & Machine LearningBiotechDeep TechAustin, US
Co-investorsAvalon BioVenturesBain Capital Life SciencesPfizer Venture InvestmentsPfizer VenturesPolaris PartnersVersant Ventures
Metagenomi Therapeutics is an in vivo genome editing company that uses genetic material sourced from natural environments (metagenomics) to develop a toolbox of editing tools for deletion, integration, and correction of genetic mutations.
BiotechDeep TechMedical DevicesBerkeley, US
Brian Thomas(Founder)inBrian Thomas Jillian Banfield(Founder)Jill Banfield(Founder)
BoardAndrew Farquharson(Director)inJak Knowles(Director)
Co-investorsCatalio Capital Management, LPSozo VenturesAgent CapitalFrazier Life SciencesHumboldtInCube Ventures+5 more
Napigen is a biotechnology company developing genome editing technology targeting the mitochondrial and chloroplast genomes.
AgTechBiotechWilmington, US
Co-investorsThe Innovation SpaceGrantham FoundationMarsBio
Secretome Therapeutics develops cell-based and secretome therapies derived from neonatal cardiac progenitor cells (nCPCs) for patients with rare and serious cardiac diseases.
BiotechHealthtechDallas, US
ANGELA SHEN(Director)HENRIK RASMUSSEN(Director)VINEET JINDAL(Executive Officer, Director)SUNJAY KAUSHAL(Director)WILLIAM NILAND(Director)
BiotechCharlestown, US
Eric Stern(Executive Officer, Director, Promoter)Aleksandar Vacic(Executive Officer, Promoter)inJames Parker Cassidy(Director)Scott Yaphe(Director)Steven E. Lufkin(Executive Officer, Director)Michael Rubin(Director)
Co-investorsSands Capital Ventures
Somatus provides value-based, integrated kidney care and a congestive heart failure management solution for patients, providers, and health plan partners.
Digital HealthHealthtechMclean, US
Ikenna Okezie(Executive Officer, Director)inAlexander Houlday(Executive Officer)inStacey Queen-Pyndell(Executive Officer)Larry Renfro(Interim President & CEO)
BoardAnna Haghgooie(Director)Anthony Welters(Director)
Co-investorsFlare Capital PartnersOptum VenturesHealthQuest CapitalBlue Venture FundsDefy PartnersLongitude Capital+7 more
Synthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems.
BiotechDeep TechHealthtechMedical DevicesRedwood City, US
Paul John Dabrowski(Executive Officer, Director)Michael Jakub Dabrowski(Executive Officer, Director)Craig Christianson(CEO)inAlex Pesch(Founder)Michael Dabrowski(Founder)Paul Dabrowski(Founder)
Co-investorsAAF Management Ltd.AME Cloud VenturesDeclaration PartnersFounders FundKhosla VenturesMenlo Ventures+11 more
Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery.
AI & Machine LearningBiotechDeep TechHealthtechWaltham, US
Judith Lieberman(Co-Founder)Daniel Koerwer(Executive Officer)inMichael Crackower(Executive Officer)inZachary McNealy(Executive Officer)Marcelo Bigal, M.D., Ph.D.(President and Chief Executive Officer)
BoardJosh Resnick(Director)in
Co-investorsAndreessen HorowitzGV (Google Ventures)SoftBank Vision FundVersant VenturesAlexandriaBiotechnology Value Fund+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.